for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Coherus Biosciences Inc

CHRS.OQ

Latest Trade

19.16USD

Change

-0.71(-3.55%)

Volume

259,889

Today's Range

18.99

 - 

19.96

52 Week Range

10.83

 - 

23.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Coherus Acquires Commercial Rights For Avastin Biosimilar In The United States

Jan 13 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS ACQUIRES COMMERCIAL RIGHTS FOR AVASTIN® BIOSIMILAR IN THE UNITED STATES.COHERUS BIOSCIENCES INC - ACCORDING TO TERMS OF AGREEMENT WITH INNOVENT, COHERUS WILL PAY UP TO $45 MILLION IN MILESTONES.COHERUS BIOSCIENCES INC - FINANCIAL TERMS FOR INNOVENT'S RITUXAN BIOSIMILAR WILL BE SAME WHEN OPTIONED..COHERUS BIOSCIENCES - TO COMMERCIALIZE INNOVENT'S BIOSIMILAR CANDIDATE TO AVASTIN IN UNITED STATES, CANADA.COHERUS BIOSCIENCES INC - TO FILE AVASTIN BLA WITH FDA IN LATE 2020 OR EARLY 2021.

KKR Biosimilar Reports 5.6% Stake In Coherus Biosciences As Of Nov. 29

Dec 2 (Reuters) - Coherus BioSciences Inc <CHRS.O>::KKR BIOSIMILAR L.P REPORTS 5.6% STAKE IN COHERUS BIOSCIENCES INC AS OF NOV 29, 2019 - SEC FILING.KKR BIOSIMILAR L.P - HAD PREVIOUSLY REPORTED 9.9% STAKE IN COHERUS BIOSCIENCES INC AS OF FEB 29, 2016.KKR BIOSIMILAR L.P-ON NOV 29, ENTERED INTO 10B5-1 SALES PLAN PURSUANT TO WHICH IT MAY SELL UP TO 1 MILLION SHARES OF COHERUS BIOSCIENCES'S COMMON STOCK.

Coherus BioSciences Reports Q3 Earnings Per Share Of $0.63

Nov 6 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.63.Q3 EARNINGS PER SHARE ESTIMATE $0.51 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q3 TOTALED $170.5 MILLION AT SEPTEMBER 30, 2019.NET PRODUCT REVENUE FOR Q3 OF 2019 WAS $111.7 MILLION.Q3 REVENUE VIEW $101.6 MILLION -- REFINITIV IBES DATA.

Coherus BioSciences Acquires Commercial Rights For Leading Lucentis Biosimilar In The United States

Nov 6 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS ACQUIRES COMMERCIAL RIGHTS FOR LEADING LUCENTIS BIOSIMILAR IN THE UNITED STATES.COHERUS ACQUIRES COMMERCIAL RIGHTS FOR LEADING LUCENTIS BIOSIMILAR IN THE UNITED STATES.COHERUS BIOSCIENCES INC - WILL MAKE A MID-SINGLE DIGIT MILLION-DOLLAR UPFRONT PAYMENT.COHERUS BIOSCIENCES INC - COMPANIES WILL SHARE PROFITS APPROXIMATELY EQUALLY.COHERUS BIOSCIENCES INC - ACQUIRED EXCLUSIVE RIGHTS FROM BIOEQ IP AG TO COMMERCIALIZE BIOEQ'S BIOSIMILAR CANDIDATE TO LUCENTIS IN U.S..

Coherus Biosciences Posts Q2 EPS Of $0.32

Aug 1 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.32.Q2 EARNINGS PER SHARE ESTIMATE $-0.00 -- REFINITIV IBES DATA.NET PRODUCT REVENUE FOR Q2 OF 2019 WAS $83.4 MILLION.CASH, CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q2 TOTALED $111.9 MILLION AT JUNE 30, 2019.

Coherus BioSciences Says Reports Victory in Pegfilgrastim Patent Dispute

July 29 (Reuters) - Coherus Biosciences Inc <CHRS.O>::US COURT OF APPEALS FOR FEDERAL CIRCUIT AFFIRMS DECISION OF A US DISTRICT COURT THAT CO'S UDENYCA DOES NOT INFRINGE AMGEN'S ASSERTED PATENT.FEDERAL CIRCUIT'S PRECEDENTIAL OPINION AFFIRMED DISTRICT COURT'S JUDGMENT IN COHERUS' FAVOR.

Amgen loses appeal against Coherus BioSciences over patent for purifying proteins

July 29 (Reuters) - u.s. Appeals court upholds dismissal of amgen <AMGN.O> patent infringement lawsuit against coherus biosciences <CHRS.O> -- court ruling:.

Coherus Biosciences Q1 Loss Per Share $0.29

May 9 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.29.Q1 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q1 TOTALED $96.4 MILLION AS OF MARCH 31, 2019.

Coherus Biosciences And Amgen Settle Trade Secrets Action

May 2 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS BIOSCIENCES AND AMGEN SETTLE TRADE SECRETS ACTION.COHERUS BIOSCIENCES - DETAILS OF SETTLEMENT ARE CONFIDENTIAL, COHERUS TO CONTINUE TO MARKET UDENYCA & PAY MID-SINGLE DIGIT ROYALTY TO AMGEN FOR 5 YEARS.COHERUS BIOSCIENCES - SETTLED TRADE SECRET ACTION BROUGHT BY AMGEN AGAINST COHERUS THAT WAS PENDING IN SUPERIOR COURT OF CALIFORNIA COUNTY OF VENTURA.

Coherus Biosciences Reports Fourth Quarter And Full Year 2018 Financial Results

Feb 28 (Reuters) - Coherus BioSciences Inc <CHRS.O>::COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.92.Q4 EARNINGS PER SHARE ESTIMATE $-0.86 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up